Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
LYON, France and CAMBRIDGE, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, has been awarded ‘Biotech Company of the Year 2023’ at the annual LSX, European Lifestars Awards Ceremony, held on November 13th in London, U.K.
The European Lifestars Awards (ELAs) are an annual event that acknowledges and celebrates the significant achievements within the life sciences sector across Europe. These awards recognize the innovation and ground-breaking achievements of the life sciences industry's most distinguished executive leaders, investors, partners, and dealmakers for their outstanding contributions to the advancement of the industry. The ‘Biotech of the Year’ award recognizes a company that has shown outstanding excellence in strategy, process, focus, and execution and has created significant value for patients, investors, employees, and the broader life science community.
"We are incredibly proud to receive the 'Biotech of the Year' award, which signifies a landmark moment for Amolyt as we mark a pivotal year of growth,” said Thierry Abribat, Ph.D., Founder and CEO of Amolyt Pharma. “This accolade reflects the tireless dedication of our team, under the expert guidance from our board of directors, and with strong support from our investors. Together, we've cultivated a culture of excellence and commitment towards patients, advancing our clinical pipeline of therapeutic peptides for rare endocrine diseases. As we edge closer to potentially bringing eneboparatide to market for patients with hypoparathyroidism, this honor is a tribute to the collective efforts and unwavering spirit of our employees since the company's launch four years ago."
Hypoparathyroidism is a rare condition defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood. Approximately 80% of the estimated 80,000 people in the U.S. and 110,000 in the European Union with hypoparathyroidism are women. Despite available treatments, patients experience persistent, life-altering symptoms and often develop complications and comorbidities that diminish quality of life and create segments of the patient population with specific clinical needs. Clinical manifestations of hypoparathyroidism impact many tissues and organ systems, in particular, the kidneys and bone.
More than half of all patients are post-menopausal women who are at an increased risk for developing osteoporosis. In a 515 hypoparathyroidism patient chart review, 17% were diagnosed with osteopenia or osteoporosis, and in the eneboparatide Phase 2a trial, 43% of patients had osteopenia. Approximately 26% of patients with hypoparathyroidism have chronic kidney disease or failure, highlighting the importance of reducing urinary calcium excretion as a key treatment goal.
Eneboparatide is an investigational therapeutic peptide designed to bind with high affinity to a specific conformation of the parathyroid hormone (PTH) receptor to produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, with the goal of consequently preventing progressive decline in kidney function and the development of chronic kidney disease. In addition to its unique receptor profile, eneboparatide is also designed to have a short half-life to potentially preserve bone integrity, an important potential benefit, since the majority of patients are peri- and postmenopausal women with an increased risk of developing osteoporosis.
About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.
LifeSci Advisors, LLC
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Company Announcement 5/20236.12.2023 14:51:46 CET | Press release
NOTICE TO CONVENE an extraordinary general meeting of Nordic Shipholding A/S in liquidation Nordic Shipholding A/S in liquidation (CVR no. 76 35 17 16) (the “Company”) hereby convenes an extraordinary general meeting to be held on Thursday 28 December 2023, at 09.00 (CET) Gorrissen Federspiel, Axel Towers, Axeltorv 2, DK-1609 Copenhagen V Agenda: 1. Presentation of the liquidator’s report 2. Presentation of the final and audited liquidation accounts for adoption 3. Resolution on liquidation of the Company with final effect 4. Any other business Complete proposals Item 1 – Presentation of the liquidator’s report Item 2 – Presentation of the final and audited liquidation accounts for adoption The liquidator proposes to the general meeting to adopt the final and audited liquidation accounts. There will be no distribution of liquidation proceeds to the shareholders of the Company in connection with the liquidation. The final and audited liquidation accounts is available for review on the C
Selskabsmeddelelse 5/20236.12.2023 14:51:46 CET | pressemeddelelse
INDKALDELSE til ekstraordinær generalforsamling i Nordic Shipholding A/S i likvidation Nordic Shipholding A/S i likvidation, CVR-nr. 76 35 17 16 (”Selskabet”) indkalder herved til ekstraordinær generalforsamling, der afholdes Torsdag den 28. december 2023, kl. 09.00, Gorrissen Federspiel, Axel Towers, Axeltorv 2, 1609 København V. Dagsorden 1. Aflæggelse af likvidators beretning 2. Forelæggelse af endeligt og revideret likvidationsregnskab til godkendelse 3. Beslutning om endelig likvidation af Selskabet 4. Eventuelt Fuldstændige forslag Punkt 1 – Aflæggelse af likvidators beretning Punkt 2 – Forelæggelse af endeligt og revideret likvidationsregnskab til godkendelse Likvidator foreslår, at det endelige likvidationsregnskab godkendes. Der vil ikke være likvidationsprovenu til fordeling blandt Selskabets aktionærer i forbindelse med likvidationens gennemførelse. Det endelige likvidationsregnskab er tilgængeligt på Selskabets hjemmeside, www.nordicshipholding.com, og er vedlagt denne indk
“GigaFarm” capable of replacing 1% of UAE food imports set for construction in Dubai Food Tech Valley6.12.2023 14:42:59 CET | Press release
DUBAI, United Arab Emirates, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Food Tech Valley has signed an agreement at COP28 with ReFarmTM to start construction on a 900,000 sq. ft. game-changing “GigaFarm”. The innovative waste-to-value farm will be capable of recycling more than 50,000 tonnes of food waste and growing two billion plants each year. ReFarmTM was established in the UAE by SSK Enterprise and Christof Global Impact (CGI) as a group of companies with focus on projects with circularity and clean technologies. The brand chose vertical farming technology developed by infrastructure supplier Intelligent Growth Solutions (IGS) and is set to start construction in mid-2024 at Dubai’s Food Tech Valley, a master development launched by His Highness Sheikh Mohammed bin Rashid Al Maktoum and being led by major Dubai property developer, Wasl. ReFarmTM has engaged its lead bank to arrange support from UK Export Finance within the UK Government’s Department for Business & Trade. In a global first,
Wolters Kluwer confirms position as a top ESG software provider by being named a Leader in Enterprise Carbon Management software6.12.2023 14:32:27 CET | Press release
PRESS RELEASE Wolters Kluwer confirms position as a top ESG software provider by being named a Leader in Enterprise Carbon Management software Independent research firm recognizes Wolters Kluwer’s Enablon as a Leader in Carbon Management software, with high scores in key data management categories. New York – December 6, 2023 – Independent research firm, Verdantix, has named Wolters Kluwer a Leader in Enterprise Carbon Management software in its Green Quadrant: Enterprise Carbon Management Software 2023 report. This report provides a comprehensive, fact-based comparison of the 19 most prominent enterprise carbon management software vendors in the market. The analysis is based on the proprietary Verdantix Green Quadrant methodology, which incorporated two-hour live briefings, desktop research, and vendor responses to a 70-point questionnaire covering 12 capability and six market-momentum categories. Wolters Kluwer, through its Enablon Vision platform, achieved high scores in the followi
Disclosure of transactions in the shares of Gabriel Holding A/S by persons discharging managerial responsibilities and closely related parties6.12.2023 14:22:32 CET | Press release
In accordance with Article 19 of the Market Abuse Regulation, Gabriel Holding A/S publishes the following transaction. Attachment Gabriel Holding AS - Announcement no 11 2023 - Managers and closely related parties' transactions